Pfizer

Trial and FDA signals

• New trial + clinical hiring Started a Phase 3 trial (NCT07794761, actual start Oct 2, 2026) (+17 other new trials); 15 clinical-operations roles open. ClinicalTrials.gov NCT07794761 (Oct 2, 2026)
  Evidence (18 events)

  • Oct 2, 2026 · ClinicalTrials.gov NCT07794761
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-10-02,type:ACTUAL}; studyFirstPostDate=2026-08-31; briefTitle='A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)'
  • Sep 30, 2026 · ClinicalTrials.gov NCT07845500
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-30,type:ACTUAL}; studyFirstPostDate=2026-09-29; briefTitle='A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overwe'
  • Sep 30, 2026 · ClinicalTrials.gov NCT07869043
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-30,type:ACTUAL}; studyFirstPostDate=2026-10-09; briefTitle='A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma'
  • Sep 24, 2026 · ClinicalTrials.gov NCT07792954
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-24,type:ACTUAL}; studyFirstPostDate=2026-08-28; briefTitle='A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obes'
  • Sep 17, 2026 · ClinicalTrials.gov NCT07823608
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-17,type:ACTUAL}; studyFirstPostDate=2026-09-16; briefTitle='A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight o'
  • Sep 9, 2026 · ClinicalTrials.gov NCT07819097
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-09,type:ACTUAL}; studyFirstPostDate=2026-09-14; briefTitle='A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults'
  • Sep 8, 2026 · ClinicalTrials.gov NCT07794748
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-08,type:ACTUAL}; studyFirstPostDate=2026-08-31; briefTitle='A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adu'
  • Aug 31, 2026 · ClinicalTrials.gov NCT07768345
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-31,type:ACTUAL}; studyFirstPostDate=2026-08-17; briefTitle='A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults'
  • Aug 26, 2026 · ClinicalTrials.gov NCT07729462
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-26,type:ACTUAL}; studyFirstPostDate=2026-07-27; briefTitle='A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine'
  • Aug 24, 2026 · ClinicalTrials.gov NCT07783425
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-24,type:ACTUAL}; studyFirstPostDate=2026-08-24; briefTitle='A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema'
  • Aug 20, 2026 · ClinicalTrials.gov NCT07772921
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-20,type:ACTUAL}; studyFirstPostDate=2026-08-19; briefTitle='A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma'
  • Aug 17, 2026 · ClinicalTrials.gov NCT07765888
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-17,type:ACTUAL}; studyFirstPostDate=2026-08-14; briefTitle='A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema'
  • Jul 30, 2026 · ClinicalTrials.gov NCT07733765
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-07-30,type:ACTUAL}; studyFirstPostDate=2026-07-29; briefTitle='A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as '
  • Jul 25, 2026 · ClinicalTrials.gov NCT07754539
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-07-25,type:ACTUAL}; studyFirstPostDate=2026-08-10; briefTitle='A Study to Evaluate 20vPnC in Healthy Chinese Infants'
  • Aug 27, 2026 · ClinicalTrials.gov NCT07792941
    leadSponsor.name='Pfizer'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-27,type:ACTUAL}; studyFirstPostDate=2026-08-28; briefTitle='A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20'
  • Jul 28, 2026 · ClinicalTrials.gov NCT07731139
    leadSponsor.name='Pfizer'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-07-28,type:ACTUAL}; studyFirstPostDate=2026-07-28; briefTitle='A Study to Learn How Different Amounts of the Study Medicine Called PF-08642534 Are Tolerated and Act in the Body of People Who Have Obesity'
  • Jul 23, 2026 · ClinicalTrials.gov NCT07725809
    leadSponsor.name='Pfizer'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-07-23,type:ACTUAL}; studyFirstPostDate=2026-07-24; briefTitle='A Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults With Overweight or Obesity'
  • Jul 24, 2026 · ClinicalTrials.gov NCT07685769
    leadSponsor.name='Pfizer'; phases=['PHASE4']; overallStatus=RECRUITING; startDateStruct={date:2026-07-24,type:ACTUAL}; studyFirstPostDate=2026-07-06; briefTitle='A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India'

Job counts as of Oct 18, 2026. All trial and FDA signals